DK1709014T3 - Antidiabetiske oxazolidindioner og thiazolidindioner - Google Patents

Antidiabetiske oxazolidindioner og thiazolidindioner

Info

Publication number
DK1709014T3
DK1709014T3 DK05722436T DK05722436T DK1709014T3 DK 1709014 T3 DK1709014 T3 DK 1709014T3 DK 05722436 T DK05722436 T DK 05722436T DK 05722436 T DK05722436 T DK 05722436T DK 1709014 T3 DK1709014 T3 DK 1709014T3
Authority
DK
Denmark
Prior art keywords
thiazolidinediones
diones
diabetes
type
oxazolidinediones
Prior art date
Application number
DK05722436T
Other languages
Danish (da)
English (en)
Inventor
Guo Q Shi
Peter T Meinke
James F Dropinski
Yong Zhang
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Application granted granted Critical
Publication of DK1709014T3 publication Critical patent/DK1709014T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/44—Two oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/62—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems having two or more ring systems containing condensed 1,3-oxazole rings
    • C07D263/64—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems having two or more ring systems containing condensed 1,3-oxazole rings linked in positions 2 and 2' by chains containing six-membered aromatic rings or ring systems containing such rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/34—Oxygen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK05722436T 2004-01-20 2005-01-18 Antidiabetiske oxazolidindioner og thiazolidindioner DK1709014T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US53763004P 2004-01-20 2004-01-20
PCT/US2005/001344 WO2005070905A1 (en) 2004-01-20 2005-01-18 Antidiabetic oxazolidinediones and thiazolidinediones

Publications (1)

Publication Number Publication Date
DK1709014T3 true DK1709014T3 (da) 2007-09-10

Family

ID=34807112

Family Applications (1)

Application Number Title Priority Date Filing Date
DK05722436T DK1709014T3 (da) 2004-01-20 2005-01-18 Antidiabetiske oxazolidindioner og thiazolidindioner

Country Status (22)

Country Link
US (1) US20070173434A1 (zh)
EP (1) EP1709014B1 (zh)
JP (1) JP2007518803A (zh)
KR (1) KR20060128921A (zh)
CN (1) CN100451008C (zh)
AT (1) ATE363475T1 (zh)
AU (1) AU2005206540B2 (zh)
BR (1) BRPI0506919A (zh)
CA (1) CA2553405A1 (zh)
CY (1) CY1106757T1 (zh)
DE (1) DE602005001265T2 (zh)
DK (1) DK1709014T3 (zh)
ES (1) ES2287908T3 (zh)
IL (1) IL176878A0 (zh)
MX (1) MXPA06008190A (zh)
NO (1) NO20063720L (zh)
NZ (1) NZ548556A (zh)
PL (1) PL1709014T3 (zh)
PT (1) PT1709014E (zh)
RU (1) RU2355682C2 (zh)
WO (1) WO2005070905A1 (zh)
ZA (1) ZA200605512B (zh)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006138328A1 (en) * 2005-06-14 2006-12-28 Merck & Co., Inc. Process for the production of antidiabetic oxazolidinediones
JP2009500355A (ja) 2005-07-06 2009-01-08 メルク エンド カムパニー インコーポレーテッド 抗糖尿病性オキサゾリジンジオン及びチアゾリジンジオン
WO2007018956A2 (en) * 2005-07-20 2007-02-15 Merck & Co., Inc. Antidiabetic oxazolidinediones and thiazolidinediones
WO2008096769A1 (ja) * 2007-02-08 2008-08-14 Daiichi Sankyo Company, Limited 置換されたセルコスポラミド誘導体を含有する医薬
US11241420B2 (en) 2007-04-11 2022-02-08 Omeros Corporation Compositions and methods for prophylaxis and treatment of addictions
US20160331729A9 (en) 2007-04-11 2016-11-17 Omeros Corporation Compositions and methods for prophylaxis and treatment of addictions
MX2020013210A (es) 2018-06-06 2021-02-26 Metavant Sciences Gmbh Metodos de tratamiento de sujetos que padecen diabetes con enfermedad renal cronica.
JP7266616B2 (ja) 2018-06-14 2023-04-28 ポクセル 糖尿病の治療において使用するためのトリアジン誘導体を含むフィルムコーティング錠剤
CN111892569A (zh) * 2019-05-05 2020-11-06 石家庄圣泰化工有限公司 4,4’-联-1,3-二氧戊环-2,2’-二酮的合成方法
CN112898265A (zh) * 2019-11-18 2021-06-04 石家庄圣泰化工有限公司 4,4’-联-1,3-二氧戊环-2,2’-二酮的制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07138258A (ja) * 1993-11-16 1995-05-30 Taiho Yakuhin Kogyo Kk チアゾリジンジオン誘導体又はその塩
US6114526A (en) * 1996-07-01 2000-09-05 Dr. Reddy's Research Foundation Heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases
EP1040102B1 (en) * 1997-12-19 2007-01-24 Merck & Co., Inc. Arylthiazolidinedione derivatives
WO2003018135A1 (en) * 2001-08-24 2003-03-06 Wyeth Holdings Corporation Method of using 5-(arylsulfonyl)-,5-(arylsulfinyl), and 5-(arylsulfanyl)-thiazolidine-2,4-diones for inhibition of farnesyl-protein transferase

Also Published As

Publication number Publication date
EP1709014B1 (en) 2007-05-30
NZ548556A (en) 2009-03-31
RU2006129930A (ru) 2008-02-27
BRPI0506919A (pt) 2007-06-05
ZA200605512B (en) 2007-11-28
IL176878A0 (en) 2006-10-31
CN100451008C (zh) 2009-01-14
ES2287908T3 (es) 2007-12-16
US20070173434A1 (en) 2007-07-26
AU2005206540B2 (en) 2009-01-08
EP1709014A1 (en) 2006-10-11
PL1709014T3 (pl) 2007-10-31
NO20063720L (no) 2006-10-09
RU2355682C2 (ru) 2009-05-20
WO2005070905A1 (en) 2005-08-04
DE602005001265D1 (de) 2007-07-12
KR20060128921A (ko) 2006-12-14
CA2553405A1 (en) 2005-08-04
ATE363475T1 (de) 2007-06-15
AU2005206540A1 (en) 2005-08-04
MXPA06008190A (es) 2006-08-31
PT1709014E (pt) 2007-08-13
DE602005001265T2 (de) 2008-01-31
CN1910163A (zh) 2007-02-07
CY1106757T1 (el) 2012-05-23
JP2007518803A (ja) 2007-07-12

Similar Documents

Publication Publication Date Title
DK1709014T3 (da) Antidiabetiske oxazolidindioner og thiazolidindioner
WO2006014262A3 (en) Indoles having anti-diabetic activity
WO2004066963A3 (en) N-cyclohexylaminocarbonyl benzenesulfonamide derivatives
WO2004019869A3 (en) Indoles having anti-diabetic activity
CA2495943A1 (en) Indoles having anti-diabetic activity
MA29352B1 (fr) Composes aromatiques fusionnes ayant une activite anti-diabetique
WO2007018956A3 (en) Antidiabetic oxazolidinediones and thiazolidinediones
IL98300A0 (en) Oxa-and thiazolidinedione hypoglycemic and hypocholesterolemic agents
MX2008011123A (es) Benzotiazoles que tienen actividad de receptor h3 de histamina.
ATE472531T1 (de) Sulfonylverbindungen als hemmer von 11-beta- hydroxysteroiddehydrogenase-1
DE60323060D1 (de) Thiazol- und oxazolderivaten als ppar modulatoren
DK1789403T3 (da) N-(phenyl-oxazol-4ylmethoxymethyl)-cyclohexyl-ravsyreamid derivater og beslægtede forbindelser som PPAR-ligander (peroxisom-proliferator-aktiverede receptorer) til behandling af hyperlipidæmi og diabetes
ATE362468T1 (de) N-substituierte indole mit anwendung in der behandlung von diabetes
DK1392295T3 (da) Carboxylsyre-substituerede oxazol-derivater til anvendelse som PPAR-alpha og -gamma-aktivatorer i behandlingen af diabetes
ATE345128T1 (de) Modulatoren der peroxisom-proliferator- aktivierten rezeptoren (ppar)
PE20060415A1 (es) Compuestos heteroaril- y fenilsulfamoilo sustituidos
PE20081199A1 (es) Derivados de azacicloalcanos como inhibidores de estearoil-coenzima a delta-9 desaturasa
NO20054396D0 (no) 3-metyl-2-(3-(2-fenyl-oksazol-4-ylmetoksy)-cykloheksankarbonyl-amino)-smorsyrederivater og lignende forbindelser som PPAR-modulatorer til behandling av type 2 diabetes og aterosklerose
ATE421490T1 (de) Verwendung von polymerpulver in pflasterfugenmörteln
ATE515494T1 (de) Neue verbindungen, deren herstellung und verwendung
WO2006022954A3 (en) Benzoureas having anti-diabetic activity
WO2004037776A3 (en) Novel compounds and their use as prar-modulators
DE602005024539D1 (de) Neue verbindungen, ihre herstellung und verwendung
DE602005022585D1 (de) Phenoxyessigsäurederivate als ppar-agonisten
RS50136B (sr) Derivati tiazolidindiona i njihova upotreba kao antidijabetika